Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | ODC-IL2 |
| Synonyms | |
| Therapy Description |
ODC-IL2 is a prodrug comprising IL2 fused to an inhibitory moiety, which, when activated, releases functional IL2 and potentially increases tumor-infiltrating lymphocytes in the tumor microenvironment (Cancer Res (2021) 81 (13_Supplement): 1745). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| ODC-IL2 | ODC IL2|ODCIL2 | ODC-IL2 is a prodrug comprising IL2 fused to an inhibitory moiety, which, when activated, releases functional IL2 and potentially increases tumor-infiltrating lymphocytes in the tumor microenvironment (Cancer Res (2021) 81 (13_Supplement): 1745). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06770764 | Phase I | ODC-IL2 | Dose Escalation and Expansion Study Evaluating ODC-IL2 in Adult Patients With Advanced or Metastatic Solid Tumors | Recruiting | USA | 0 |